Literature DB >> 20430394

An update on the relationships between rheumatoid arthritis and atherosclerosis.

Zeynep Ozbalkan1, Cumali Efe, Mustafa Cesur, Sibel Ertek, Narin Nasiroglu, Kaspar Berneis, Manfredi Rizzo.   

Abstract

Rheumatoid arthritis is a chronic inflammatory disease. Cardiovascular events are the most important cause of mortality and morbidity in patients with rheumatoid arthritis. Beyond the traditional cardiovascular risk factors, chronic systemic inflammation has been shown to be a crucial factor in atherosclerosis development and progression from endothelial dysfunction to plaque rupture and thrombosis. Many studies have shown that atherosclerosis is not a passive event like accumulation of lipids in the vessel walls; by contrast, it represents an active inflammation of the vessels. Inflammatory cells such as macrophages, monocytes and T cells play important roles in the development of both rheumatoid arthritis and atherosclerosis. In this article we analyse the relationships between rheumatoid arthritis and atherosclerosis.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20430394     DOI: 10.1016/j.atherosclerosis.2010.03.035

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  22 in total

1.  Evaluation of early atherosclerosis in patients with inflammatory bowel disease.

Authors:  Hasan Kayahan; Ismail Sari; Nesat Cullu; Fahize Yuksel; Serdal Demir; Mesut Akarsu; Yigit Goktay; Belkis Unsal; Hale Akpinar
Journal:  Dig Dis Sci       Date:  2012-04-01       Impact factor: 3.199

Review 2.  ADAMTS proteases: key roles in atherosclerosis?

Authors:  Rebecca C Salter; Tim G Ashlin; Alvin P L Kwan; Dipak P Ramji
Journal:  J Mol Med (Berl)       Date:  2010-07-22       Impact factor: 4.599

3.  Relationship between body composition and both cardiovascular risk factors and lung function in systemic sclerosis.

Authors:  Paola Caramaschi; Domenico Biasi; Cristian Caimmi; Giovanni Barausse; Davide Gatti; Marcello Ferrari; Sara Pieropan; Dania Sabbagh; Silvano Adami
Journal:  Clin Rheumatol       Date:  2013-09-20       Impact factor: 2.980

4.  Infliximab, a TNF-α inhibitor, reduces 24-h ambulatory blood pressure in rheumatoid arthritis patients.

Authors:  S Yoshida; T Takeuchi; T Kotani; N Yamamoto; K Hata; K Nagai; T Shoda; S Takai; S Makino; T Hanafusa
Journal:  J Hum Hypertens       Date:  2013-09-05       Impact factor: 3.012

Review 5.  Blood/Brain Biomarkers of Inflammation After Stroke and Their Association With Outcome: From C-Reactive Protein to Damage-Associated Molecular Patterns.

Authors:  Alejandro Bustamante; Alba Simats; Andrea Vilar-Bergua; Teresa García-Berrocoso; Joan Montaner
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

6.  Effect of hypertension on echocardiographic parameters in rheumatoid arthritis.

Authors:  A Temiz; S Ozcan; F Gökmen; E Gazi; A Barutcu; A Bekler; B Altun; A Akbal; F Güneş; H Şen
Journal:  Z Rheumatol       Date:  2014-12       Impact factor: 1.372

7.  Epicardial adipose tissue thickness, flow-mediated dilatation of the brachial artery, and carotid intima-media thickness: Associations in rheumatoid arthritis patients.

Authors:  A Temiz; F Gökmen; E Gazi; A Akbal; A Barutçu; A Bekler; B Altun; Y Z Tan; F Güneş; H Şen
Journal:  Herz       Date:  2014-08-21       Impact factor: 1.443

8.  2K1C-activated Angiotensin II (Ang II) exacerbates vascular damage in a rat model of arthritis through the ATR/ERK1/2 signaling pathway.

Authors:  Ying Zhang; Xuexia Luo; Yue Zhou; Huaxun Wu; Jingyu Chen; Ying Wang; Danian Chen; Zhouwei Xu; Shangxue Yan; Wei Wei
Journal:  Inflamm Res       Date:  2017-06-26       Impact factor: 4.575

9.  Lack of cardiovascular risk assessment in inflammatory arthritis and systemic lupus erythematosus patients at a tertiary care center.

Authors:  Stephanie O Keeling; Michelle Teo; Daisy Fung
Journal:  Clin Rheumatol       Date:  2011-04-19       Impact factor: 2.980

10.  Platelet-rich plasma inhibits inflammatory factors and represses rheumatoid fibroblast-like synoviocytes in rheumatoid arthritis.

Authors:  Shichao Tong; Ji Liu; Changqing Zhang
Journal:  Clin Exp Med       Date:  2017-01-24       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.